Short answer
Cryoport, Inc. (CYRX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results released August 6, 2026, covering quarter ended June 30, 2026.
Cryoport, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results released August 6, 2026, covering quarter ended June 30, 2026
- Detailed financial results and management commentary provided in Exhibit 99.1
- Regulation FD disclosure not treated as filed under Exchange Act Section 18 absent specific incorporation by reference
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $49.0M, up 8% YoY; H1 revenue $96.8M, up 12%, led by Life Sciences Services growth
- Services revenue rose 15% to $28.0M, with BioStorage/BioServices up 25% to $5.6M
- Adjusted EBITDA turned positive at $0.4M versus negative $0.9M, marking progress toward profitability
- Gross margin slipped to 46.6% from 47.0% as Products margin fell to 42.2% from 44.9%
- Clinical-trial support reached 779 and commercial CGT support 22 therapies, strengthening future services demand visibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cryoport, Inc. 8-K filings
Get the next CYRX 8-K as it lands
Follow CYRX for push alerts, or ask the research agent what this filing means.